Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19

Jane A. O’Halloran, Eyal Kedar, Kevin J. Anstrom, Matthew W. McCarthy, Emily R. Ko, Patricia Segura Nunez, Cynthia Boucher, P. Brian Smith, Reynold A. Panettieri Jr, Sabina Mendivil Tuchia de Tai, Martin Maillo, Akram Khan, Alfredo J. Mena Lora, Matthias Salathe, Gerardo Capo, Daniel Rodríguez Gonzalez, Thomas F. Patterson, Christopher Palma, Horacio Ariza, Maria Patelli Lima, Anne M. Lachiewicz, John Blamoun, Esteban C. Nannini, Eduardo Sprinz, Analia Mykietiuk, Radica Alicic, Adriana M. Rauseo, Cameron R. Wolfe, Britta Witting, Daniel K. Benjamin Jr, Steven E. McNulty, Pearl Zakroysky, Susan Halabi, Sandra Butler, Jane Atkinson, Stacey J. Adam, Richard Melsheimer, Soju Chang, Lisa LaVange, Michael Proschan, Samuel A. Bozzette, William G. Powderly, the ACTIV-1 IM study group members
doi: https://doi.org/10.1101/2022.09.22.22280245

Article Information

doi 
https://doi.org/10.1101/2022.09.22.22280245
History 
  • September 23, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Jane A. O’Halloran1,
  2. Eyal Kedar2,
  3. Kevin J. Anstrom3,
  4. Matthew W. McCarthy4,
  5. Emily R. Ko5,
  6. Patricia Segura Nunez6,
  7. Cynthia Boucher7,
  8. P. Brian Smith8,
  9. Reynold A. Panettieri Jr9,
  10. Sabina Mendivil Tuchia de Tai10,
  11. Martin Maillo11,
  12. Akram Khan12,
  13. Alfredo J. Mena Lora13,
  14. Matthias Salathe14,
  15. Gerardo Capo15,
  16. Daniel Rodríguez Gonzalez16,
  17. Thomas F. Patterson17,
  18. Christopher Palma18,
  19. Horacio Ariza19,
  20. Maria Patelli Lima20,
  21. Anne M. Lachiewicz3,
  22. John Blamoun21,
  23. Esteban C. Nannini22,
  24. Eduardo Sprinz23,
  25. Analia Mykietiuk24,
  26. Radica Alicic25,
  27. Adriana M. Rauseo1,
  28. Cameron R. Wolfe5,
  29. Britta Witting4,
  30. Daniel K. Benjamin Jr26,
  31. Steven E. McNulty27,
  32. Pearl Zakroysky8,
  33. Susan Halabi8,
  34. Sandra Butler28,
  35. Jane Atkinson7,
  36. Stacey J. Adam29,
  37. Richard Melsheimer30,
  38. Soju Chang7,
  39. Lisa LaVange3,
  40. Michael Proschan31,
  41. Samuel A. Bozzette7,
  42. William G. Powderly32,#,
  43. the ACTIV-1 IM study group members*
  1. 1Washington University in St. Louis School of Medicine
  2. 2St. Lawrence Health System
  3. 3University of North Carolina
  4. 4Weill Cornell Medicine
  5. 5Duke University Medical Center
  6. 6Hospital Nacional Hipolito Unanue
  7. 7National Center for Advancing Translational Sciences
  8. 8Duke Clinical Research Institute, Duke University School of Medicine
  9. 9Robert Wood Johnson Medical School
  10. 10Hospital Central de la Fuerza Aerea del Peru
  11. 11Sanatorio Diagnostico
  12. 12Oregon Health and Science University
  13. 13University of Illinois at Chicago
  14. 14University of Kansas Medical Center
  15. 15Trinitas Hospital
  16. 16Nuevo Hospital Civil de Guadalajara Juan I. Menchaca
  17. 17University of Texas Health Science Center at San Antonio
  18. 18University of Rochester School of Medicine and Dentistry
  19. 19Clinica Central S.A.
  20. 20Hospital e Maternidade Celso Pierro - PUC Campinas
  21. 21MidMichigan Medical Center
  22. 22Departamento de Enfermedades Infecciosas, Sanatorio Britanico
  23. 23Hospital de Clinicas de Porto Alegre HCPA
  24. 24Instituto Medico Platense
  25. 25Providence Medical Research Center
  26. 26Duke Clinical Research Institute, Duke University Medical Center
  27. 27Duke Clinical Research Insitute, Duke University School of Medicine
  28. 28Technical Resources International
  29. 29Foundation for the National Institutes of Health
  30. 30Janssen Pharmaceuticals
  31. 31National Institute of Allergy and Infectious Diseases
  32. 32Washington University in St Louis School of Medicine
  1. ↵#Address for correspondence:
    William G. Powderly, MD, Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110. Email: Wpowderly{at}wustl.edu.
Back to top
Posted September 23, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19
Jane A. O’Halloran, Eyal Kedar, Kevin J. Anstrom, Matthew W. McCarthy, Emily R. Ko, Patricia Segura Nunez, Cynthia Boucher, P. Brian Smith, Reynold A. Panettieri Jr, Sabina Mendivil Tuchia de Tai, Martin Maillo, Akram Khan, Alfredo J. Mena Lora, Matthias Salathe, Gerardo Capo, Daniel Rodríguez Gonzalez, Thomas F. Patterson, Christopher Palma, Horacio Ariza, Maria Patelli Lima, Anne M. Lachiewicz, John Blamoun, Esteban C. Nannini, Eduardo Sprinz, Analia Mykietiuk, Radica Alicic, Adriana M. Rauseo, Cameron R. Wolfe, Britta Witting, Daniel K. Benjamin Jr, Steven E. McNulty, Pearl Zakroysky, Susan Halabi, Sandra Butler, Jane Atkinson, Stacey J. Adam, Richard Melsheimer, Soju Chang, Lisa LaVange, Michael Proschan, Samuel A. Bozzette, William G. Powderly, the ACTIV-1 IM study group members
medRxiv 2022.09.22.22280245; doi: https://doi.org/10.1101/2022.09.22.22280245
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area